Combining PET Radiomic Features With MYC Gene Rearrangement Results in High Prediction of Outcome in Diffuse Large B-cell Lymphoma

J.J. Eertink[1], G.J.C. Zwezerijnen[2], S.E. Wiegers[1], M.E.D. Chamuleau[1], P.J. Lugtenburg[3], D. de Jong[4], B. Ylstra[4], M. Mendeville[4], U. Dührsen[5], A. Hüttmann[5], C. Schmitz[5], J. Richter[6], W. Klapper[6], O.S. Hoekstra[2], H.C.W. de Vet[7], R. Boellaard[2], J.M. Zijlstra[1]

[1]Amsterdam UMC, Vrije Universiteit Amsterdam, department of Hematology, Cancer Center Amsterdam, Amsterdam, The Netherlands
[2]Amsterdam UMC, Vrije Universiteit Amsterdam, department of Radiology and Nuclear Medicine, Cancer Center Amsterdam, Amsterdam, The Netherlands
[3]Erasmus MC Cancer Institute, University Medical Center Rotterdam, department of Hematology, Rotterdam, The Netherlands
[4]Amsterdam UMC, Vrije Universiteit Amsterdam, department of Pathology, Cancer Center Amsterdam, Amsterdam, The Netherlands
[5]Department of Hematology, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany
[6]Department of Pathology, Hematopathology Section, University Hospital Schleswig-Holstein, Christian-Albrecht-University of Kiel, Kiel, Germany
[7]Amsterdam UMC, Vrije Universiteit Amsterdam, department of Epidemiology and Data Science, Amsterdam Public Health research institute, Amsterdam, Netherlands

Introduction
Genetic abnormalities, such as MYC oncogene rearrangements, contribute to the outcome heterogeneity in diffuse large B-cell lymphoma (DLBCL) patients. These rearrangements occur in 10-15% of DLBCL patients and have been associated with a poor prognosis. Recently, radiomics features extracted from PET/CT scans have shown to be predictive of outcome. The aim of this study was to investigate if the ability to predict outcome in DLBCL can be improved by combining different clinical, radiomics and genetic features.

Methods
323 DLBCL patients from the HOVON-84, HOVON-130, and PETAL trials with a baseline PET/CT scan and a minimum follow-up of two years were included. *MYC* status was assessed using Fluorescence in situ hybridization (FISH). 245 patients were *MYC* negative, whereas 25 patients had a *MYC* rearrangement and 57 patients had *MYC* and *BCL2* and/or *BCL6* rearrangements. Lesions were delineated using a semi-automated preselection of ^{18}F-FDG avid structures defined by a SUV4.0 threshold using the ACCURATE tool. Next, 5 conventional PET features (maximum standardized uptake value (SUV$_{max}$), SUV$_{peak}$, SUV$_{mean,}$ metabolic tumor volume (MTV) and total lesion glycolysis and 18 dissemination features were extracted. Dissemination features were pertaining to distance between lesions, differences in uptake between lesions and differences in volume between lesions. Logistic regression with backward feature selection was used to predict 2-year time to progression, defined as time from baseline PET/CT to progression. We tested the predictive value of 4 models. 1) a clinical model using individual components of the international prognostic index (IPI): Ann Arbor stage (categorical), WHO performance status (categorical), lactate dehydrogenase (LDH) levels (dichotomous) and age (continuous), 2) a model that included clinical and genetic predictors: *MYC* status (categorical) and IPI components, 3) a model that included radiomics features: 5 conventional PET and 18 dissemination features and 4) a model that combined clinical and genetic predictors with radiomics features. Model performance was assessed using repeated cross-validation (5-fold, 1000 repeats) yielding the cross-validated area under the curve of the receiver-operator-characteristics curve (CV-AUC). To match prevalence of *MYC*-positive patients with real-world prevalence (Rosenwald et al, JCO 2019) all 245 MYC-negative patients were used for each repeat, and 10 *MYC*-FISH_positive DLBCL patients and 20

patients with *MYC* and *BCL2* and/or *BCL6* rearrangements were selected using random stratified sampling. Regression coefficients were averaged over all folds to calculate the probability of progression for all patients. High- and low-risk groups were defined based on prevalence of events and the diagnostic performance was assessed using positive- and negative predictive values.

Results
The highest model performance for the clinical model was observed when combining Ann Arbor stage, LDH and extranodal involvement and yielded in a CV-AUC of 0.69 (95% confidence interval (CI): 0.52-0.83). *MYC* status combined with WHO performance status, LDH and extranodal involvement yielded an improved CV-AUC of 0.71 (95% CI: 0.52-0.86). The highest model performance for the radiomics model was observed for MTV combined with the maximum distance between the largest lesion and any other lesions ($Dmax_{bulk}$), the maximum difference in SUV_{peak} between two lesions ($DSUVpeak_{patient}$) and the maximum difference in volume between two lesions ($DVol_{patient}$) yielding a CV-AUC of 0.77 (95% CI: 0.62-0.90). The optimal combined model included *MYC* status, WHO performance status, LDH, MTV, $Dmax_{patient}$, $DSUVpeak_{patient}$ and $DVol_{patient}$ after backward feature selection and yielded a CV-AUC of 0.77 (95% CI: 0.60 – 0.90). The positive predictive value was highest for the combined model (53.0%) and increased by 20% compared to the optimal clinical model (33.1%). Negative predictive values were comparable between models and ranged between 85.8-88.1%.

Conclusions
Prediction models using ^{18}F-FDG PET/CT radiomics features at baseline aids in identifying DLBCL patients at high risk for relapse. The positive predictive value increased when radiomics features were added to the clinical and genetic parameters. Therefore, radiomics features can increase the efficiency of clinical trials by only selecting poor prognosis patients.